Atherogenics' CEO to Present Company Update at Chase H&Q 19th Annual Healthcare Conference on January 9, 2001
ATLANTA, Jan. 3 /PRNewswire/ -- AtheroGenics, Inc. (Nasdaq: AGIX - news), an Atlanta-based emerging pharmaceutical company, announced today that Russell M. Medford, M.D., Ph.D., president and chief executive officer of the company, will present a company overview and an update on the progress in its drug development program for the treatment of rheumatoid arthritis at the Chase H&Q 19th Annual Healthcare Conference, being held at the Westin St. Francis in San Francisco on January 9, 2001. AtheroGenics will present from 8:30 - 8:55 a.m.
The presentation will be webcast live from the Chase H&Q Conference and available for replay at chasehq.com .
AtheroGenics, Inc., through its proprietary vascular protectant drug discovery technology platform, is focused on the discovery, development and commercialization of novel therapeutics for the treatment of chronic inflammatory diseases such as heart disease (atherosclerosis), asthma and arthritis. The company designed its lead product candidate, AGI-1067, to benefit patients with coronary artery disease, which is atherosclerosis of the blood vessels of the heart. AGI-1067 has recently completed dosing in a 300-patient Phase II clinical study for post-angioplasty restenosis. <snip> |
